Peritoneal Cancer - Pipeline Review, H2 2016

Date: September 21, 2016
Pages: 676
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P1D31F5E446EN
Leaflet:

Download PDF Leaflet

Peritoneal Cancer - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Peritoneal Cancer - Pipeline Review, H2 2016’, provides an overview of the Peritoneal Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Peritoneal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peritoneal Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape of Peritoneal Cancer
  • The report reviews pipeline therapeutics for Peritoneal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Peritoneal Cancer therapeutics and enlists all their major and minor projects
  • The report assesses Peritoneal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Peritoneal Cancer
Reasons to buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Peritoneal Cancer
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Peritoneal Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope:
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Peritoneal Cancer Overview
Therapeutics Development
Peritoneal Cancer - Therapeutics under Development by Companies
Peritoneal Cancer - Therapeutics under Investigation by Universities/Institutes
Peritoneal Cancer - Pipeline Products Glance
Peritoneal Cancer - Products under Development by Companies
Peritoneal Cancer - Products under Investigation by Universities/Institutes
Peritoneal Cancer - Companies Involved in Therapeutics Development
Peritoneal Cancer - Therapeutics Assessment
Drug Profiles
Peritoneal Cancer - Dormant Projects
Peritoneal Cancer - Discontinued Products
Peritoneal Cancer - Product Development Milestones
Appendix 662

LIST OF TABLES

Number of Products under Development for Peritoneal Cancer, H2 2016
Number of Products under Development for Peritoneal Cancer - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Development by Companies, H2 2016 (Contd..4)
Number of Products under Development by Companies, H2 2016 (Contd..5)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Development by Companies, H2 2016 (Contd..5)
Products under Development by Companies, H2 2016 (Contd..6)
Products under Investigation by Universities/Institutes, H2 2016
Peritoneal Cancer - Pipeline by AbbVie Inc, H2 2016
Peritoneal Cancer - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016
Peritoneal Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2016
Peritoneal Cancer - Pipeline by Aduro BioTech, Inc., H2 2016
Peritoneal Cancer - Pipeline by Advanced Accelerator Applications S.A., H2 2016
Peritoneal Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2016
Peritoneal Cancer - Pipeline by Amgen Inc., H2 2016
Peritoneal Cancer - Pipeline by Astex Pharmaceuticals, Inc., H2 2016
Peritoneal Cancer - Pipeline by AstraZeneca Plc, H2 2016
Peritoneal Cancer - Pipeline by Atara Biotherapeutics, Inc., H2 2016
Peritoneal Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H2 2016
Peritoneal Cancer - Pipeline by Bayer AG, H2 2016
Peritoneal Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016
Peritoneal Cancer - Pipeline by Boston Biomedical, Inc., H2 2016
Peritoneal Cancer - Pipeline by Celldex Therapeutics, Inc., H2 2016
Peritoneal Cancer - Pipeline by Celsion Corporation, H2 2016
Peritoneal Cancer - Pipeline by CerRx, Inc., H2 2016
Peritoneal Cancer - Pipeline by Cerulean Pharma, Inc., H2 2016
Peritoneal Cancer - Pipeline by Clovis Oncology, Inc., H2 2016
Peritoneal Cancer - Pipeline by Critical Outcome Technologies Inc., H2 2016
Peritoneal Cancer - Pipeline by CritiTech, Inc., H2 2016
Peritoneal Cancer - Pipeline by CTI BioPharma Corp., H2 2016
Peritoneal Cancer - Pipeline by Dr. Reddy's Laboratories Limited, H2 2016
Peritoneal Cancer - Pipeline by EirGenix Inc., H2 2016
Peritoneal Cancer - Pipeline by Eisai Co., Ltd., H2 2016
Peritoneal Cancer - Pipeline by Eli Lilly and Company, H2 2016
Peritoneal Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H2 2016
Peritoneal Cancer - Pipeline by Exelixis, Inc., H2 2016
Peritoneal Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Peritoneal Cancer - Pipeline by Galena Biopharma, Inc., H2 2016
Peritoneal Cancer - Pipeline by Ganymed Pharmaceuticals AG, H2 2016
Peritoneal Cancer - Pipeline by Gene Techno Science Co., Ltd., H2 2016
Peritoneal Cancer - Pipeline by Genelux Corporation, H2 2016
Peritoneal Cancer - Pipeline by Genentech, Inc., H2 2016
Peritoneal Cancer - Pipeline by Genor BioPharma Co., Ltd., H2 2016
Peritoneal Cancer - Pipeline by Glycotope GmbH, H2 2016
Peritoneal Cancer - Pipeline by Gradalis Inc., H2 2016
Peritoneal Cancer - Pipeline by Hemispherx Biopharma, Inc., H2 2016
Peritoneal Cancer - Pipeline by ImmunoGen, Inc., H2 2016
Peritoneal Cancer - Pipeline by Immunovaccine, Inc., H2 2016
Peritoneal Cancer - Pipeline by Incyte Corporation, H2 2016
Peritoneal Cancer - Pipeline by Innate Pharma S.A., H2 2016
Peritoneal Cancer - Pipeline by Johnson & Johnson, H2 2016
Peritoneal Cancer - Pipeline by Juno Therapeutics Inc., H2 2016
Peritoneal Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2016
Peritoneal Cancer - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016
Peritoneal Cancer - Pipeline by Mabion SA, H2 2016
Peritoneal Cancer - Pipeline by MabVax Therapeutics Holdings, Inc., H2 2016
Peritoneal Cancer - Pipeline by Mateon Therapeutics Inc, H2 2016
Peritoneal Cancer - Pipeline by MedImmune, LLC, H2 2016
Peritoneal Cancer - Pipeline by Medivation, Inc., H2 2016
Peritoneal Cancer - Pipeline by Merck & Co., Inc., H2 2016
Peritoneal Cancer - Pipeline by Merck KGaA, H2 2016
Peritoneal Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2016
Peritoneal Cancer - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
Peritoneal Cancer - Pipeline by MolMed S.p.A., H2 2016
Peritoneal Cancer - Pipeline by Mycenax Biotech Inc., H2 2016
Peritoneal Cancer - Pipeline by Neopharm Ltd., H2 2016
Peritoneal Cancer - Pipeline by Novartis AG, H2 2016
Peritoneal Cancer - Pipeline by OBI Pharma, Inc., H2 2016
Peritoneal Cancer - Pipeline by Oncobiologics, Inc., H2 2016
Peritoneal Cancer - Pipeline by Oncolix, Inc., H2 2016
Peritoneal Cancer - Pipeline by Oncolytics Biotech Inc., H2 2016
Peritoneal Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H2 2016
Peritoneal Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
Peritoneal Cancer - Pipeline by Oxford BioMedica Plc, H2 2016
Peritoneal Cancer - Pipeline by Pharma Mar, S.A., H2 2016
Peritoneal Cancer - Pipeline by PsiOxus Therapeutics Limited, H2 2016
Peritoneal Cancer - Pipeline by Quest PharmaTech Inc., H2 2016
Peritoneal Cancer - Pipeline by Richter Gedeon Nyrt., H2 2016
Peritoneal Cancer - Pipeline by Samyang Holdings Corporation, H2 2016
Peritoneal Cancer - Pipeline by Sanofi Pasteur SA, H2 2016
Peritoneal Cancer - Pipeline by Sotio a.s., H2 2016
Peritoneal Cancer - Pipeline by TapImmune Inc., H2 2016
Peritoneal Cancer - Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2016
Peritoneal Cancer - Pipeline by Tesaro, Inc., H2 2016
Peritoneal Cancer - Pipeline by TetraLogic Pharmaceuticals, H2 2016
Peritoneal Cancer - Pipeline by Tyrogenex, Inc., H2 2016
Peritoneal Cancer - Pipeline by Vascular Biogenics Ltd., H2 2016
Peritoneal Cancer - Pipeline by VentiRx Pharmaceuticals, Inc., H2 2016
Peritoneal Cancer - Pipeline by Vyriad, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Peritoneal Cancer - Dormant Projects, H2 2016
Peritoneal Cancer - Dormant Projects (Contd..1), H2 2016
Peritoneal Cancer - Dormant Projects (Contd..2), H2 2016
Peritoneal Cancer - Dormant Projects (Contd..3), H2 2016
Peritoneal Cancer - Dormant Projects (Contd..4), H2 2016
Peritoneal Cancer - Discontinued Products, H2 2016 669

LIST OF FIGURES

Number of Products under Development for Peritoneal Cancer, H2 2016
Number of Products under Development for Peritoneal Cancer - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


Peritoneal Tumor - Pipeline Review, H1 2014 US$ 1,500.00 Mar, 2014 · 69 pages
Thymus Cancer - Pipeline Review, H1 2016 US$ 1,700.00 Apr, 2016 · 109 pages
Uterine Cancer - Pipeline Review, H1 2014 US$ 1,500.00 Apr, 2014 · 50 pages
Oropharyngeal Cancer - Pipeline Review, H1 2016 US$ 2,000.00 May, 2016 · 136 pages
Gastric Cancer - Pipeline Review, H1 2016 US$ 1,700.00 Apr, 2016 · 962 pages

Ask Your Question

Peritoneal Cancer - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: